Iltamiocel is under clinical development by Cook MyoSite and currently in Phase III for Fecal Incontinence. According to GlobalData, Phase III drugs for Fecal Incontinence does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Iltamiocel LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Iltamiocel overview

Cell therapy is under development for the treatment of fecal incontinence,tongue dysphagia and urological diseases such as stress urinary incontinence and underactive bladder (Hypoactive Bladder). The theraopeuticcandidate is administered through  intramuscular route. Autologous muscle-derived cell (AMDCs) possesses a high myogenic capacity and effectively regenerates both skeletal and cardiac muscle. It was also under development for advanced ischemic heart failure. It is formulated as solution for stress urinary incontinence

For a complete picture of Iltamiocel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.